Category

News
Welcome to issue 36 of Multiple Myeloma Research Review. The use of ixazomib-based induction therapy in routine clinical practice is relatively uncommon for several reasons, so the first study for this issue is useful, as it describes the effectiveness and safety of such treatment in a multicentre cohort of real-world patients. US research has confirmed...
Continue Reading
This article was originally published on Multiple Myeloma Today ABSTRACT BACKGROUND: Patients with hematological malignancies (HM), including multiple myeloma (MM), frequently suffer from immune deficiency-associated infectious complications because of both the disease and the treatment. Alarming results from China and the UK confirm the vulnerability of HM patients to severe acute respiratory syndrome coronavirus 2...
Continue Reading
Dear All It is nice to see the days warming up even though in Wellington we seem to be getting perpetual rain. Spare a thought for our UK brethren who will be having a lockdown until Easter. My London based son has managed to flee to a Greek island and says he will look at...
Continue Reading
This article was originally published on The Limbic Australian patients with multiple myeloma face critical shortcomings in genetic testing at diagnosis and access to new ‘standard of care’ treatments such as daratumumab, a leading haematologist has told a Parliamentary inquiry. Professor Andrew Spencer of Monash University says the current reimbursement model is unsuited to handling...
Continue Reading
This article was originally published on Cancer Network Results from a study presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting suggested that radiation therapy administered to patients with relapsed or refractory multiple myeloma awaiting CAR T-cells is safe and feasible without worsening rates of severe cytokine release syndrome (CRS), neurotoxicity, or hematologic...
Continue Reading
This article was originally published on Cancer Therapy Advisor As the coronavirus disease 2019 (COVID-19) pandemic evolves into subsequent waves in many parts of the world, there are many outstanding questions about the outcomes of infection for patients with multiple myeloma, specifically around the severity of outcomes, prognostic factors, and the effect of different treatments....
Continue Reading
This article originally published on Multiple Myeloma Toady ABSTRACT Multiple myeloma is a bone marrow neoplasia with an incidence of 6/100,000/year in Europe. While the disease remains incurable, the development of novel treatments such as autologous stem cell transplantation, proteasome inhibitors and monoclonal antibodies has led to an increasing subset of patients living with long-term...
Continue Reading
Saturday 28 November 10am – 12pm Come along to our Hamilton Myeloma Patient Seminar, hosted by Myeloma New Zealand and Leukaemia & Blood Cancer New Zealand. During the morning, we will hear from Dr Henry Chan (Waitemata DHB) who will discuss the latest updates on myeloma and treatment. Saturday 28 November10am – 12pmThe Link Community...
Continue Reading
This article was originally published on Docwire News Sarah Holstein, MD, PhD, associate professor of medicine in the Division of Oncology & Hematology at the University of Nebraska Medical Center, discusses the multiple myeloma (MM) treatment pipeline and how the introduction of these agents may change the treatment landscape. In part two of this interview...
Continue Reading
This article was originally posted on Docwire News. DocWire News sat down with Saad Usmani, M.D., MBA, FACP to discuss an indirect treatment comparison study which assesses DARZALEX® (daratumumab) Plus Lenalidomide and Dexamethasone (D-Rd) and Bortezomib-Containing Regimens in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma. To continue reading this article on Docwire News.
Continue Reading
1 2 3 4 29

Floor 7, 90 The Terrace
Wellington Central
New Zealand